Zosano Pharma Corporation (ZSAN)
ZSANPrice: $0.56
Fair Value: 🔒
🔒score
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan... more
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeu... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Steven Lo |
| IPO Date | 2015-01-27 | CAGR | -0.26% |
| Employees | 40 | Website | www.zosanopharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ZSAN chart loading...
Fundamentals
Technicals
| Enterprise Value | $-6.53M | P/E Ratio | -1.94 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1.89 |
| P/CF Ratio | -2.26 | P/FCF Ratio | — |
| EPS | $-0.29 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 36.72% | Gross Margin | -0.01% |
| Operating Margin | -37.88% | Profit Margin | -38.36% |
| ROE | -0.75% | ROA | -0.62% |
| ROCE | -0.8% | Current Ratio | 1.04 |
| Quick Ratio | 1.04 | Cash Ratio | 0.99 |
| Debt/Equity | 0.29 | Interest Coverage | -157.33 |
| Altman Z Score | — | Piotroski Score | — |